https://www.cooley.digital/references/ 

h1>A List Of Danish Biotech Companies</h1> <img src="https://i.imgur.com/R4ZqQhR.jpg" alt="List Of Danish Biotech Companies" align="right" style="max-width:32% max-height:242px; width:auto; margin:0px 10px; height:auto;"> <p>If you're seeking accurate data on Danish biotech companies, you should consider using a service like BoldData?. The database is compiled by the company and includes data from Central Business Register and Danish Chambers of Commerce. This database will assist you to create a successful marketing strategy to promote your biotech business. BoldData?'s database is regularly updated and can help you create an effective and targeted campaign.

/p> <h2>Orphazyme

/h2>

p>A biopharmaceutical company that is in the late stages Orphazyme is in the process of developing a new treatment for the neurodegenerative disease Niemann-Pick type C. The company has a lead drug in development called Arimoclomol. The company plans to file a marketing authorization application to the EMA in second-half 2020.

/p> <p>The company has a long history of focusing its efforts on rare diseases. Marja Jaattela and Thomas Kirkegaard founded the company in 2010. They've focused their efforts on the storage of lysosomes in particular.

/p> <h2>Symphogen

/h2>

p>French pharmaceutical company Servier has signed a deal to purchase Symphogen Symphogen, the Danish biotech company that has built an antibody discovery platform to aid in cancer treatments. Servier's pipeline of antibodies will be strengthened through this acquisition. Since over two years, the companies have been working together within the field of immuno-oncology. The acquisition will allow Servier to fully leverage Symphogen's expertise and technology.

/p> <p>Symphogen has a solid management team which is diverse and knowledgeable. Kirsten Drejer has a long-standing experience in the industry with a track record of building an impressive pipeline and supporting Symphogen achieve great financial results. The company also has assets that have positive clinical evidence.

/p> <h2>Galecto Biotech

/h2>

p>Galecto Biotech, a Danish biotech company, creates new treatments for serious diseases. Galectin-3 is the most prominent product candidate. This protein is involved in numerous immune and inflammation processes. The company is currently conducting clinical trials to treat the idiopathic lung disease. It has partnered with Bristol-Myers Squibb, and plans to conduct more clinical trials to treat fibrotic disorders.

/p> <p>Galecto Biotech's products are based on research technology that targets the galectin-3 receptor. The company's product development teams are focused on the development and commercialization of chemically derived therapeutic drugs but they're not restricted to this. The company is also working on the final stages of clinical trials for its galectin modulator, which could eventually lead to a cure for asthma and nasal polyposis.

/p> <h2>Novo Nordisk

img width="472" src="https://blog.gainapp.com/wp-content/uploads/2020/03/marketing-client-agency-relationship.jpg">

/h2>

p>In the United USA, Dicerna Pharmaceuticals has been bought by the biotech company. Dicerna had developed medicines built on RNA interference which blocks genes that cause certain diseases.

/p> <p>The company plans to invest a total of 17 billion Danish kroner in three new manufacturing facilities. The company will also expand the existing facility in Kalundborg, Denmark. These new facilities will create more capacity throughout the global value chain. They will also improve the production of injectable and oral products. The new facilities will have the latest production technology.

/p> <h2>Novozymes

/h2>

p>Novozymes is a Danish biotechnology company, specializes in industrial enzymes. The company has many market segments and its revenues are mainly generated in the following industries that include bio-energy, agriculture, and household care. Novozymes was founded in 1988, and is headquartered in Copenhagen in Denmark.

/p> <p>The Danish biotech company has a long tradition of success in product roll-out. Its predecessor, Nordisk Insulinlaboratorium, launched its first enzyme, trypsin in 1941. This enzyme was initially utilized to soften leather. The company also invented the fermentation process for enzyme production. It created the first enzyme used in detergent production in the latter part of the 1980s: lipolase. This enzyme improved the freshness and quality of white breads and buns.

/p> <h2>Lilly

/h2>

p>Denmark is home to a variety of leading biotech companies. Biotechnology is used by these companies to fight cancer, create vaccines, as well as provide other medical solutions. Oncology Venture ApS is a company that specializes in research and development related to cancer. Other notable companies include AquaGreen?, a Danish biotech engineering firm, and STipe Therapeutics, which harnesses the innate immune system to fight cancer. Acesion Pharma, a Danish biotech company, is also developing drugs for atrial fibrillation.

/p> <p>The medical technology and biotechnology industries have a long history of Denmark and Sweden. They are among the top five pharmaceutical exporters around the world. Denmark is also home to one of the highest per-capita R&D expenditures in the European pharmaceutical industry, which is second only to Switzerland. The Medicon Valley, which is a cross-border cluster between Denmark and Sweden, accounts for 60 percent of Scandinavian pharmaceutical activities.

/p> <h2>Innovent

/h2>

p>Innovent Biotech has recently secured exclusive rights to market and sell Eli Lilly's cancer drugs in the mainland of China. The deal will allow Innovent to control pricing as well as marketing, sales, and distribution of these medications. Both companies will collaborate on the development and distribution of treatments to address the major unmet medical requirements, such as cancer or eczema.

/p> <p>Innovent has a substantial pipeline, including 16 potential products. Seven are currently in clinical development. Seven also partnered with Eli Lilly to develop three Chinese cancer treatments. Another Danish biotech company, Ascentage, has partnered with Oriza Ventures and the Chinese state-owned SDIC Fund Management.

/p> <iframe height="282" allowfullscreen="true" frameborder="0" src="https://www.youtube.com/embed/ccGs550TSjk" width="505" style="margin:0px auto; display: block;"></iframe>


トップ   編集 凍結 差分 バックアップ 添付 複製 名前変更 リロード   新規 一覧 単語検索 最終更新   ヘルプ   最終更新のRSS
Last-modified: 2022-09-17 (土) 13:00:55 (587d)